KFAS
CAPR icon

Keating Financial Advisory Services’s Capricor Therapeutics CAPR Stock Holding History

Keating Financial Advisory Services’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10K Buy
416
+412
+10,300% +$12.5K ﹤0.01% 1244
2026
Q1 		$122 Buy
+4
New +$107 ﹤0.01% 2399

Other funds holding CAPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Keating Financial Advisory Services's CAPR Position: Q2 2026 in Review

Keating Financial Advisory Services increased its Capricor Therapeutics (CAPR) stake by 10,300% in Q2 2026, buying an estimated $12.5K and bringing the position to 416 shares worth $10K. The position accounts for ﹤0.01% of the portfolio, ranked #1244.

Keating Financial Advisory Services first reported a position in CAPR in Q1 2026 and has held it in 2 quarters since. 170 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

  • Keating Financial Advisory Services held 416 shares of Capricor Therapeutics worth $10K as of Q2 2026.
  • Keating Financial Advisory Services bought 412 Capricor Therapeutics shares in Q2 2026, an estimated $12.5K.
  • Capricor Therapeutics made up ﹤0.01% of Keating Financial Advisory Services's portfolio in Q2 2026, its #1244 holding.
  • Keating Financial Advisory Services first reported a position in Capricor Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 170 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.